PharmiWeb.com - Global Pharma News & Resources
20-Dec-2018

Cholesterylester Transfer Protein (CETP) Inhibitor Pipeline Insights, 2018 Report - ResearchAndMarkets.com

The "Cholesterylester Transfer Protein (CETP) Inhibitor -Pipeline Insight, 2018" drug pipelines has been added to ResearchAndMarkets.com'soffering.

Cholesterylester Transfer Protein (CETP) Inhibitor - Pipeline Insight, 2018 report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cholesterylester Transfer Protein (CETP) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Descriptive coverage of pipeline development activities for Cholesterylester Transfer Protein (CETP) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products

4. Comparative Analysis

5. Pipeline Products in Clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

6. Pipeline Products in Non-clinical Stages

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment: Active Products

  • Pipeline Assessment by Route of Administration
  • Pipeline Assessment by Stage and Route of Administration
  • Pipeline Assessment by Molecule Type
  • Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

  • Product Description
  • Research and Development
  • Product Development Activities
  • Reason for dormancy/discontinuation

Companies Mentioned

  • Kowa Pharmaceutical
  • Bristol-Myers Squibb
  • Bayer
  • Mitsubishi Tanabe Pharma Corporation
  • Merck & Co
  • Chong Kun Dang
  • Amgen
  • Eli Lilly
  • DalCor Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/smjcg2/cholesterylester?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20181220005599/en/

Editor Details

Last Updated: 20-Dec-2018